Share on StockTwits

Regeneron Pharmaceuticals (NASDAQ:REGN) Director Joseph L. Goldstein sold 2,000 shares of the stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $347.65, for a total value of $695,300.00. Following the sale, the director now directly owns 6,000 shares in the company, valued at approximately $2,085,900. The sale was disclosed in a document filed with the SEC, which is available at this link.

Several analysts have recently commented on the stock. Analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $349.00 to $373.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Separately, analysts at Roth Capital reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 5th. Finally, analysts at Deutsche Bank raised their price target on shares of Regeneron Pharmaceuticals from $410.00 to $425.00 in a research note on Tuesday, August 5th. They now have a “buy” rating on the stock. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $345.94.

Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 348.62 on Monday. Regeneron Pharmaceuticals has a 52-week low of $227.64 and a 52-week high of $352.49. The stock has a 50-day moving average of $316. and a 200-day moving average of $308.5. The company has a market cap of $34.998 billion and a price-to-earnings ratio of 99.21.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter in the previous year, the company posted $1.73 earnings per share. The company’s revenue for the quarter was up 45.4% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $10.14 EPS for the current fiscal year.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.